Relapse in APL remains a significant clinical challenge, particularly among patients presenting with high-risk features such as elevated WBC counts (18), FLT3 mutations (19, 20), and specific genetic alterations (21). The gene discussed is FLT3; the disease is acute promyelocytic leukemia.